Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Socazolimab Neoadjuvant Therapy in Esophageal Squamous Cell Carcinoma
NCT04460066Phase 2Unknown
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Nov 2020
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of socazolimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Lee's Pharmaceutical Holdings Limited. Status: unknown.
02
Drugs
socazolimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04460066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04460066.